Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...
The manufacturer of the weight loss jab Wegovy has been reprimanded for allegedly failing to disclose or accurately report ...
Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...
Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.
And that sounds to me like Novo Nordisk may have just discovered two new revenue streams it can extract from Ozempic. While not super cheap today, at 26 times trailing earnings and with growth ...
The active ingredient in Ozempic and Wegovy was linked to reduced cravings for drinking alcohol among people with alcohol use ...
Symptoms of NAION can include blurred vision, peripheral vision loss, dark spots in vision, and changes in color perception. Though the exact mechanism is not fully understood, researchers hypothesize ...
A new study (the first clinical trial of its kind) has shown that the GLP-1 agonist semaglutide — known by the brand name ...